90 related articles for article (PubMed ID: 162258)
1. Kainic acid animal model predicts therapeutic agents in Huntington's chorea.
Borison RL; Diamond BI
Trans Am Neurol Assoc; 1979; 104():67-9. PubMed ID: 162258
[No Abstract] [Full Text] [Related]
2. [Toxic action of kainic acid as a model of Huntington chorea and epilepsy (review)].
Levin SL; Sytinskiĭ IA
Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(5):754-63. PubMed ID: 6224382
[No Abstract] [Full Text] [Related]
3. Angiotensin converting enzyme in kainic acid--injected striata.
Singh EA; McGeer EG
Ann Neurol; 1978 Jul; 4(1):85-6. PubMed ID: 211933
[TBL] [Abstract][Full Text] [Related]
4. Kainic acid: insights from a neurotoxin into the pathophysiology of Huntington's disease.
Coyle JT; Ferkany JW; Zaczek R
Neurobehav Toxicol Teratol; 1983; 5(6):617-24. PubMed ID: 6142425
[TBL] [Abstract][Full Text] [Related]
5. [Activity of dopaminergic neurons of the substantia nigra following lesions of the neostriatum by kainic acid].
Doudet D; Gross C; Bioulac B
C R Seances Soc Biol Fil; 1984; 178(3):298-306. PubMed ID: 6238656
[TBL] [Abstract][Full Text] [Related]
6. [Model of choreic movement in monkey--contribution for understanding the mechanism of chorea in Huntington's disease].
Kanazawa I
Jikken Dobutsu; 1990 Apr; 39(2):168-72. PubMed ID: 2141819
[No Abstract] [Full Text] [Related]
7. The relationships of aging changes in the basal ganglia to manifestations of Huntington's chorea.
Finch CE
Ann Neurol; 1980 May; 7(5):406-11. PubMed ID: 6446874
[No Abstract] [Full Text] [Related]
8. [Recent neurobiological and related pharmaco-therapeutic acquisitions in Huntington's chorea].
Carolei A; Del Castillo G
Clin Ter; 1979 Sep; 90(6):591-621. PubMed ID: 43793
[No Abstract] [Full Text] [Related]
9. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease.
Alexi T; Hughes PE; van Roon-Mom WM; Faull RL; Williams CE; Clark RG; Gluckman PD
Exp Neurol; 1999 Sep; 159(1):84-97. PubMed ID: 10486177
[TBL] [Abstract][Full Text] [Related]
10. [Huntington's chorea and sulpiride].
Petit H; Havet JP
Lille Med; 1971; 16(7):1019-21. PubMed ID: 4255994
[No Abstract] [Full Text] [Related]
11. Citicoline is not protective in experimental models of Huntington's disease.
Mievis S; Levivier M; Vassart G; Brotchi J; Ledent C; Blum D
Neurobiol Aging; 2007 Dec; 28(12):1944-6. PubMed ID: 17064815
[TBL] [Abstract][Full Text] [Related]
12. Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives.
Vécsei L; Beal MF
Biol Psychiatry; 1996 Jun; 39(12):1061-3. PubMed ID: 8780845
[No Abstract] [Full Text] [Related]
13. [Present possibilities and prospects in the treatment of Huntington's chorea].
Petit H
Therapeutique; 1972 Nov; 48(9):605-8. PubMed ID: 4265448
[No Abstract] [Full Text] [Related]
14. Minocycline is protective in a mouse model of Huntington's disease.
Hersch S; Fink K; Vonsattel JP; Friedlander RM
Ann Neurol; 2003 Dec; 54(6):841; author reply 842-3. PubMed ID: 14681897
[No Abstract] [Full Text] [Related]
15. Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease.
Diguet E; Rouland R; Tison F
Ann Neurol; 2003 Dec; 54(6):841-2. PubMed ID: 14681898
[No Abstract] [Full Text] [Related]
16. Decreased receptor-binding sites for kainic acid in brains of patients with Huntington's disease.
London ED; Yamamura HI; Bird ED; Coyle JT
Biol Psychiatry; 1981 Feb; 16(2):155-62. PubMed ID: 6452910
[TBL] [Abstract][Full Text] [Related]
17. Huntington's disease and its animal model: alterations in kainic acid binding.
Beaumont K; Maurin Y; Reisine TD; Fields JZ; Spokes E; Bird ED; Yamamura HI
Life Sci; 1979 Feb; 24(9):809-16. PubMed ID: 156298
[No Abstract] [Full Text] [Related]
18. Drug discovery and development for Huntington's disease - an orphan indication with high medical need.
Heitz F; La Rosa S; Gonzalez-Couto E; Gaviraghi G; Terstappen GC
IDrugs; 2008 Sep; 11(9):653-60. PubMed ID: 18763216
[TBL] [Abstract][Full Text] [Related]
19. Fluoxetine-induced exacerbation of chorea in Huntington's disease? A case report.
Chari S; Quraishi SH; Jainer AK
Pharmacopsychiatry; 2003 Jan; 36(1):41-3. PubMed ID: 12649776
[No Abstract] [Full Text] [Related]
20. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Kumar P; Kumar A
Eur J Pharmacol; 2009 Aug; 615(1-3):91-101. PubMed ID: 19445928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
